Evidence map›Paper›PMID 28176224›Full record

ArticleInternational journal of hematology2017

Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.

Norio Komatsu, Keita Kirito, Kazuya Shimoda, Takayuki Ishikawa, Kohshi Ohishi, Kazuma Ohyashiki, Naoto Takahashi, Hikaru Okada, Taro Amagasaki, Toshio Yonezu and 1 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. komatsun@juntendo.ac.jp.
Keita KiritoDepartment of Hematology and Oncology, University of Yamanashi, Yamanashi, 409-3898, Japan.
Kazuya ShimodaDepartment of Gastroenterology and Hematology, University of Miyazaki, Miyazaki, 889-1692, Japan.
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, 650-0047, Japan.
Kohshi OhishiBlood Transfusion Service, Mie University, Tsu, Mie, 514-8507, Japan.
Kazuma OhyashikiDepartment of Hematology, Tokyo Medical University, Tokyo, 160-8402, Japan.
Naoto TakahashiDepartment of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, 010-8502, Japan.
Hikaru OkadaNovartis Pharma KK, Tokyo, 105-6333, Japan.
Taro AmagasakiNovartis Pharma KK, Tokyo, 105-6333, Japan.
Toshio YonezuNovartis Pharma KK, Tokyo, 105-6333, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University, Fukuoka, 812-8582, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID28176224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.